Great Valley Advisor Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19.6M | Sell |
77,720
-679
| -0.9% | -$146K | 0.31% | 84 |
|
|
2026
Q1 | $17.1M | Buy |
78,399
+7,089
| +10% | +$1.57M | 0.31% | 84 |
|
|
2025
Q4 | $16.3M | Sell |
71,310
-3,462
| -5% | -$789K | 0.31% | 82 |
|
|
2025
Q3 | $17.3M | Sell |
74,772
-3,809
| -5% | -$776K | 0.35% | 76 |
|
|
2025
Q2 | $14.6M | Sell |
78,581
-3,546
| -4% | -$659K | 0.32% | 82 |
|
|
2025
Q1 | $17.2M | Sell |
82,127
-2,003
| -2% | -$389K | 0.37% | 67 |
|
|
2024
Q4 | $14.9M | Buy |
84,130
+1,254
| +2% | +$231K | 0.33% | 80 |
|
|
2024
Q3 | $16.4M | Buy |
82,876
+1,661
| +2% | +$310K | 0.4% | 68 |
|
|
2024
Q2 | $13.9M | Buy |
81,215
+9,270
| +13% | +$1.54M | 0.39% | 70 |
|
|
2024
Q1 | $13.1M | Buy |
71,945
+8,407
| +13% | +$1.45M | 0.4% | 68 |
|
|
2023
Q4 | $9.85M | Buy |
63,538
+1,936
| +3% | +$282K | 0.35% | 71 |
|
|
2023
Q3 | $9.18M | Buy |
61,602
+5,159
| +9% | +$757K | 0.38% | 69 |
|
|
2023
Q2 | $7.6M | Buy |
56,443
+6,225
| +12% | +$913K | 0.32% | 79 |
|
|
2023
Q1 | $8M | Buy |
50,218
+8,360
| +20% | +$1.28M | 0.37% | 68 |
|
|
2022
Q4 | $6.76M | Sell |
41,858
-537
| -1% | -$82.3K | 0.35% | 73 |
|
|
2022
Q3 | $5.69M | Sell |
42,395
-2,379
| -5% | -$341K | 0.32% | 78 |
|
|
2022
Q2 | $6.86M | Buy |
44,774
+5,922
| +15% | +$905K | 0.38% | 66 |
|
|
2022
Q1 | $5.92M | Buy |
38,852
+1,231
| +3% | +$179K | 0.35% | 77 |
|
|
2021
Q4 | $4.73M | Sell |
37,621
-181
| -0.5% | -$21.4K | 0.29% | 91 |
|
|
2021
Q3 | $4.08M | Buy |
37,802
+859
| +2% | +$98.2K | 0.28% | 92 |
|
|
2021
Q2 | $4.11M | Buy |
36,943
+5,320
| +17% | +$599K | 0.3% | 84 |
|
|
2021
Q1 | $3.42M | Buy |
31,623
+9,170
| +41% | +$981K | 0.33% | 72 |
|
|
2020
Q4 | $2.41M | Sell |
22,453
-267
| -1% | -$25.7K | 0.25% | 91 |
|
|
2020
Q3 | $1.99M | Buy |
22,720
+1,820
| +9% | +$171K | 0.24% | 94 |
|
|
2020
Q2 | $2.05M | Buy |
20,900
+3,602
| +21% | +$317K | 0.34% | 81 |
|
|
2020
Q1 | $1.32M | Buy |
17,298
+2,192
| +15% | +$187K | 0.35% | 87 |
|
|
2019
Q4 | $1.34M | Sell |
15,106
-1,868
| -11% | -$155K | 0.3% | 103 |
|
|
2019
Q3 | $1.28M | Buy |
16,974
+422
| +3% | +$28.9K | 0.31% | 95 |
|
|
2019
Q2 | $1.2M | Sell |
16,552
-4,036
| -20% | -$317K | 0.3% | 99 |
|
|
2019
Q1 | $1.66M | Buy |
20,588
+1,238
| +6% | +$101K | 0.53% | 50 |
|
|
2018
Q4 | $1.75M | Buy |
+19,350
| New | +$1.7M | 0.66% | 34 |
|
Other funds holding ABBV
Great Valley Advisor Group's ABBV Position: Q2 2026 in Review
Great Valley Advisor Group reduced its AbbVie (ABBV) stake by 0.87% in Q2 2026, selling an estimated $146K and leaving 77,720 shares worth $19.6M. The position accounts for 0.31% of the portfolio, ranked #84.
Great Valley Advisor Group first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Great Valley Advisor Group held 77,720 shares of AbbVie worth $19.6M as of Q2 2026.
- Great Valley Advisor Group sold 679 AbbVie shares in Q2 2026, an estimated $146K.
- AbbVie made up 0.31% of Great Valley Advisor Group's portfolio in Q2 2026, its #84 holding.
- Great Valley Advisor Group first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Great Valley Advisor Group's 13F filing for Q2 2026, filed 10 Aug 2026.